Home Cart Sign in  
Chemical Structure| 365462-23-3 Chemical Structure| 365462-23-3

Structure of Darexaban
CAS No.: 365462-23-3

Chemical Structure| 365462-23-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Darexaban is a potent and orally effective factor Xa inhibitor with IC50 value of 54.6nM.

Synonyms: YM150

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Darexaban

CAS No. :365462-23-3
Formula : C27H30N4O4
M.W : 474.55
SMILES Code : O=C(NC1=CC=CC(O)=C1NC(C2=CC=C(N3CCN(C)CCC3)C=C2)=O)C4=CC=C(OC)C=C4
Synonyms :
YM150
MDL No. :MFCD16620506
InChI Key :IJNIQYINMSGIPS-UHFFFAOYSA-N
Pubchem ID :9912771

Safety of Darexaban

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01118559 Healthy|Pharmacokinetics of YM... More >>150 Less << PHASE1 COMPLETED 2025-01-10 Kyushu, Japan
NCT00937820 Venous Thromboembolism PHASE3 COMPLETED 2025-12-10 Chubu, Japan|Chugoku, Japan|Ka... More >>nsai, Japan|Kantou, Japan|Touhoku, Japan Less <<
NCT01028950 Venous Thromboembolism PHASE3 COMPLETED 2025-04-10 Chubu, Japan|Chugoku, Japan|Ka... More >>nsai, Japan|Kantou, Japan|Touhoku, Japan Less <<
NCT01125657 Healthy Volunteer|Pharmacokine... More >>tics of YM150 Less << PHASE1 COMPLETED 2025-03-10 Kyushu, Japan
NCT00937911 Venous Thromboembolism PHASE3 COMPLETED 2025-04-10 Chubu, Japan|Chugoku, Japan|Ho... More >>kkaido, Japan|Kansai, Japan|Kantou, Japan|Kyusyu, Japan|Shikoku, Japan|Touhoku, Japan Less <<
NCT01657981 Pharmacokinetics|Healthy Male ... More >>Subjects Less << PHASE1 COMPLETED 2025-03-07 PRA International EDS NL, Zuid... More >>laren, 9471 GP, Netherlands Less <<
NCT00353678 Thromboembolism PHASE2 COMPLETED 2025-08-07 Innsbruck, 6020, Austria|Vienn... More >>a, 1090, Austria|Vienna, 1130, Austria|Foca, 73300, Bosnia and Herzegovina|Sarajevo, 71000, Bosnia and Herzegovina|Tuzla, 75000, Bosnia and Herzegovina|Brno, 66250, Czech Republic|Kladno, 27259, Czech Republic|Praha, 18000, Czech Republic|Trebic, 67401, Czech Republic|Copenhagen, 2300, Denmark|Herlev, 2730, Denmark|Horsholm, 2970, Denmark|Silkeborg, 8600, Denmark|Jyvaskyla, 40620, Finland|Oulu, 90220, Finland|Berlin, 12157, Germany|Frankfurt am Main, 60528, Germany|Halle, 06112, Germany|Kremmen OT Somerfeld, 16766, Germany|Markgroningen, 71706, Germany|Schwandorf, 92421, Germany|Athens, 166 73, Greece|Melissia, 151 27, Greece|Bologna, 40136, Italy|Milano, 20123, Italy|Milano, 20162, Italy|Parma, 43100, Italy|Pavia, 27100, Italy|Pietra Ligure, 17027, Italy|Reggio Emilia, 42100, Italy|Rozzano, 20089, Italy|S. Donato Milanese, 20097, Italy|Udine, 33100, Italy|Riga, LV 1004, Latvia|Riga, LV 1005, Latvia|Valmiera, 4201, Latvia|Kaunas, LT-50009, Lithuania|Vilnius, LT-04130, Lithuania|Elverum, 2409, Norway|Trondheim, 7006, Norway|Tynset, 2500, Norway|Bialystok, 15-276, Poland|Katowice, 40-635, Poland|Krakow, 31-826, Poland|Lublin, 20-718, Poland|Lublin, 20-951, Poland|Warszawa, 00-909, Poland|Chelyabinsk, 454026, Russian Federation|Moscow, 111539, Russian Federation|Moscow, 117869, Russian Federation|Moscow, 119049, Russian Federation|Moscow, 129327, Russian Federation|Nizhniy Novgorod, 603155, Russian Federation|Orenburg, 460000, Russian Federation|Saint Petersburg, 194291, Russian Federation|Samara, 443095, Russian Federation|St Petersburg, 195067, Russian Federation|Volgograd, 400040, Russian Federation|Belgrade, 11000, Serbia|Kragujevac, 34000, Serbia|Nis, 18000, Serbia|Novi Sad, 21000, Serbia|Subotica, 24000, Serbia|Banska Bysterica, 974 01, Slovakia|Ruzomberok, 034 26, Slovakia|Caceres, 10003, Spain|Cantoria, 39120, Spain|Castellon, 12004, Spain|Madrid, 28006, Spain|Madrid, 28035, Spain|Madrid, 28040, Spain|Madrid, 28046, Spain|Valencia, 46010, Spain|Falkoping, 52185, Sweden|Goteborg, 41685, Sweden|Kalmar, 39185, Sweden|Motala, 59185, Sweden|Stockholm, 11883, Sweden Less <<
NCT01125670 Healthy Volunteer|Pharmacokine... More >>tics of YM150 Less << PHASE1 COMPLETED 2025-04-10 Kyushu, Japan

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.54mL

2.11mL

1.05mL

21.07mL

4.21mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories